What is primary mediastinal large B-cell lymphoma?
Primary mediastinal large B-cell lymphoma (PMBCL) is a fast-growing type of non-Hodgkin lymphoma. It starts in the mediastinum, the space in the middle of the chest behind the breastbone and between the lungs.
It develops from B lymphocytes that live in the thymus, a small gland in the chest. For this reason it is also called primary mediastinal (thymic) large B-cell lymphoma.
PMBCL mainly affects young adults, especially women in their 20s and 30s. It usually causes a large mass in the chest that can press on the airways and the big veins returning blood to the heart.
Although it was once grouped with diffuse large B-cell lymphoma (DLBCL), PMBCL is now known to be a separate disease. In its biology, it has much in common with classic Hodgkin lymphoma.
The outlook is very good. With modern chemoimmunotherapy, around 85-95% of people are cured.
1. Key facts at a glance
| Feature | Details |
|---|---|
| How common | About 2-4% of non-Hodgkin lymphomas and about 6-10% of large B-cell lymphomas |
| Typical age | Median age about 35; most patients are 20-40 |
| Sex | More common in women (about 2 to 1) |
| Site | Anterior mediastinum (front of the chest) |
| Typical size | Often over 10 cm (bulky) at diagnosis |
| Key biology | Gains of chromosome 9p24.1, raising PD-L1 and PD-L2; activated JAK-STAT and NF-kappaB pathways |
| Main treatment | Rituximab-based chemotherapy (DA-EPOCH-R or R-CHOP), with radiotherapy for some |
| Outlook | Long-term survival about 85-95% |
2. Causes and biology
The cause of PMBCL is unknown. It is not inherited and not contagious, and no lifestyle cause has been found.
The lymphoma cells carry characteristic acquired gene changes:
| Change | Effect |
|---|---|
| 9p24.1 gain or amplification | Increases PD-L1 and PD-L2, proteins that switch off immune attack. This is why PD-1 blocking drugs work in relapsed PMBCL |
| JAK-STAT activation | Changes in JAK2, SOCS1 and STAT6 drive cell growth |
| NF-kappaB activation | Supports cell survival |
| CIITA changes | Reduce MHC molecules on the cell surface, helping the lymphoma hide from the immune system |
These changes are shared with nodular sclerosis classic Hodgkin lymphoma. Rare tumours with features of both are called mediastinal grey zone lymphoma.
3. How does it look?
3.1 On the body
Most of the changes are inside the chest, but some can be seen:
| Sign | What it looks like |
|---|---|
| Swollen face and neck | Puffiness, especially in the morning, from pressure on the superior vena cava |
| Swollen veins | Prominent, widened veins on the neck, chest and upper arms |
| Red or purple face | Particularly when bending forward or lying down |
| Swollen arms | Fluid build-up in one or both arms |
| Lumps above the collarbone | Enlarged lymph nodes in the lower neck in some people |
3.2 On scans
| Test | Typical findings |
|---|---|
| Chest X-ray | A widened mediastinum |
| CT scan | A large, lobulated mass in the front of the chest, often over 10 cm. It may surround or compress the blood vessels and windpipe, invade the chest wall, lung or pericardium, and cause fluid around the lungs or heart |
| PET-CT | Very high uptake of the tracer (FDG); used for staging and to judge response at the end of treatment |
PMBCL usually stays in the chest. Spread to the bone marrow at diagnosis is uncommon. At relapse, it can spread to unusual places such as the kidneys, adrenal glands, liver, ovaries and the brain.
3.3 Under the microscope
| Feature | Description |
|---|---|
| Cells | Medium to large B cells, often with clear (pale) cytoplasm |
| Fibrosis | Bands of fibrous tissue divide the tumour into small compartments (compartmentalising sclerosis) |
| Markers | CD20 and CD79a positive; often CD23, MAL and CD30 (usually weaker than in Hodgkin lymphoma); PD-L1 often positive |
| Negative markers | Usually CD15 negative and no surface immunoglobulin, which helps to tell it apart from Hodgkin lymphoma |
4. Symptoms
Symptoms develop over weeks to a few months, as the mass grows quickly.
4.1 Chest symptoms
| Symptom | Cause |
|---|---|
| Dry cough | Pressure on the windpipe or airways |
| Breathlessness | Pressure on the airways, fluid around the lungs, or pressure on the heart |
| Chest pain or tightness | Mass pressing on surrounding structures |
| Swelling of the face, neck and arms, headache | Superior vena cava syndrome, a common feature of PMBCL |
| Hoarse voice or difficulty swallowing | Pressure on nerves or the gullet |
| Breathlessness lying flat | Mass pressing on the airway when lying down |
4.2 General symptoms
| Symptom | Details |
|---|---|
| B symptoms | Fever, drenching night sweats and weight loss affect a minority |
| Tiredness | Common |
4.3 When to get urgent help
Get urgent medical help if you have:
- worsening breathlessness or noisy breathing
- rapid swelling of the face, neck or arms
- fainting or a fast heartbeat with breathlessness (a possible sign of fluid around the heart)
Large chest masses can be risky during anaesthesia, so the biopsy is planned carefully, often using a CT-guided needle rather than general anaesthesia.
5. Diagnosis
| Test | Purpose |
|---|---|
| Biopsy | CT-guided core needle biopsy or a minor surgical biopsy (mediastinoscopy or mediastinotomy); confirms the diagnosis |
| Immunohistochemistry | Confirms the B-cell type and separates PMBCL from Hodgkin lymphoma, grey zone lymphoma, thymoma and germ cell tumour |
| PET-CT | Staging and baseline for response |
| Blood tests | Full blood count, LDH (often raised), liver and kidney function, HIV and hepatitis B and C tests |
| Heart scan (echocardiogram) | Before anthracycline chemotherapy; also checks for fluid around the heart |
| Pregnancy test and fertility discussion | Important because many patients are young |
5.1 Staging
Most people have stage I or II disease, limited to the chest and neighbouring nodes. Doctors also note bulk (a mass of 10 cm or more), raised LDH and spread outside the lymph tissue, which affect the outlook.
6. Treatment
Treatment aims at cure and should be planned by an experienced lymphoma team.
6.1 First-line chemoimmunotherapy
| Regimen | Details |
|---|---|
| DA-EPOCH-R | Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab, given over 6 cycles as a continuous infusion. In a US study, 93% were free of disease events and 97% alive at about 5 years, mostly without radiotherapy |
| R-CHOP | Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone every 2 or 3 weeks, for 6 cycles. Often followed by radiotherapy if the end-of-treatment PET is positive |
| R-CHOP-14 or other intensified regimens | Used in some European centres |
6.2 Radiotherapy
Radiotherapy to the chest used to be routine. It increases the long-term risk of breast cancer, heart disease and lung damage, which matters in young women.
The IELSG37 trial (2024) showed that people whose PET scan shows a complete metabolic response after chemoimmunotherapy can safely skip radiotherapy, as outcomes were very similar with or without it. Radiotherapy is now mainly used when the PET scan shows remaining active disease.
6.3 Relapsed or refractory disease
About 10-15% of people do not respond or relapse, almost always within the first 12-18 months. Options include:
| Option | Details |
|---|---|
| CAR T-cell therapy | Axicabtagene ciloleucel or lisocabtagene maraleucel; PMBCL patients were included in pivotal trials and respond well |
| PD-1 inhibitors | Pembrolizumab is approved for relapsed PMBCL; in KEYNOTE-170, responses were often long-lasting |
| Nivolumab plus brentuximab vedotin | In the CheckMate 436 trial, about 70% responded |
| Salvage chemotherapy and autologous stem cell transplant | For chemotherapy-sensitive relapse |
| Allogeneic stem cell transplant | Occasionally, after other options |
6.4 Side effects of treatment
| Treatment | Main side effects |
|---|---|
| Chemotherapy | Low blood counts and infections, hair loss, nausea, mouth sores, tingling in the hands and feet (vincristine), tiredness |
| Doxorubicin | Heart damage in a small number, sometimes years later |
| Rituximab | Infusion reactions; reactivation of hepatitis B |
| Radiotherapy | Sore throat, cough; later, raised risk of breast cancer, heart disease and thyroid problems |
| PD-1 inhibitors | Immune inflammation of the thyroid, skin, bowel, liver or lungs |
| CAR T cells | Cytokine release syndrome (fever, low blood pressure) and neurological effects such as confusion |
| Fertility | Chemotherapy may reduce fertility; egg, embryo or sperm storage can be discussed before treatment |
7. Outlook (prognosis)
| Situation | Approximate outcome |
|---|---|
| After first-line treatment | About 85-95% are cured |
| Complete metabolic response on end-of-treatment PET | Very low risk of relapse |
| Relapse after 2 years | Rare |
| Relapsed or refractory disease | Historically poor; CAR T cells and PD-1 inhibitors now lead to long-term remission in a proportion of patients |
8. Follow-up and late effects
| What | How often |
|---|---|
| Clinic review and blood tests | Every 3 months for 2 years, then less often up to 5 years |
| Scans | Not routinely after a negative end-of-treatment PET; done if symptoms appear |
| Heart checks | Long-term, after anthracyclines or chest radiotherapy |
| Breast screening | Earlier and more frequent for women who had chest radiotherapy before age 36 |
| Thyroid tests | Yearly after radiotherapy to the neck or upper chest |
9. Special situations and daily life
| Topic | Key points |
|---|---|
| Pregnancy | PMBCL is sometimes diagnosed in pregnancy because it affects young women. Chemotherapy can often be given safely in the second and third trimesters; a specialist team plans timing, delivery and imaging that avoids radiation |
| Superior vena cava syndrome | Usually improves within days of starting chemotherapy and steroids; a stent or blood thinners are needed only occasionally |
| Work and study | Many people continue some work or study during treatment, but tiredness is common, especially towards the end of chemotherapy |
| Infection precautions | Report a temperature of 38 C or more straight away during chemotherapy |
| Vaccines | Inactivated vaccines (such as flu and COVID-19) are recommended; live vaccines are avoided during and soon after treatment |
| Smoking | Stopping smoking lowers the risk of lung and heart problems, especially after chest radiotherapy |
| Emotional support | A cancer diagnosis in young adulthood can affect relationships, work and finances; counsellors, nurse specialists and charities can help |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is PMBCL the same as Hodgkin lymphoma? | No. Both often start in the chest of young adults and share some biology, but PMBCL is a B-cell non-Hodgkin lymphoma treated with different regimens |
| Why is my chest mass still visible after treatment? | Scar tissue often remains. PET-CT shows whether it still contains active lymphoma |
| Will I need radiotherapy? | Not if the end-of-treatment PET scan shows a complete metabolic response, based on current evidence |
| Can I have children after treatment? | Many people do. Discuss fertility preservation with your team before starting chemotherapy |
| Can it come back? | Relapse is uncommon and usually happens in the first 1-2 years; after that, the risk becomes very small |
Resources
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Campo, E. et al. (2022) ‘The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee’, Blood, 140(11), pp. 1229-1253.
- Rosenwald, A. et al. (2003) ‘Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma’, Journal of Experimental Medicine, 198(6), pp. 851-862.
- Green, M.R. et al. (2010) ‘Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma’, Blood, 116(17), pp. 3268-3277.
- Dunleavy, K. et al. (2013) ‘Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma’, New England Journal of Medicine, 368(15), pp. 1408-1416.
- Rieger, M. et al. (2011) ‘Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study’, Annals of Oncology, 22(3), pp. 664-670.
- Dunleavy, K. (2017) ‘Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies’, Hematology: American Society of Hematology Education Program, 2017(1), pp. 298-303.
- Martelli, M. et al. (2024) ‘Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results’, Journal of Clinical Oncology, 42(34), pp. 4071-4083.
- Armand, P. et al. (2019) ‘Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma’, Journal of Clinical Oncology, 37(34), pp. 3291-3299.
- Zinzani, P.L. et al. (2023) ‘Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170’, Blood, 142(2), pp. 141-145.
- Zinzani, P.L. et al. (2019) ‘Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study’, Journal of Clinical Oncology, 37(33), pp. 3081-3089.
- Neelapu, S.S. et al. (2017) ‘Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma’, New England Journal of Medicine, 377(26), pp. 2531-2544.
- Abramson, J.S. et al. (2020) ‘Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study’, The Lancet, 396(10254), pp. 839-852.
- National Cancer Institute (2026) Adult Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.